ADVAGENE BIOPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.75 TWD | +45.38% |
|
+61.14% | +5.31% |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 1.36B 44.07B |
|---|---|---|---|---|---|
| Net income 2022 | -118M -3.84B | Net income 2023 | -92M -2.99B | EV / Sales 2022 | - |
| Net cash position 2022 | 101M 3.28B | Net cash position 2023 | 125M 4.07B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-12.5
x | P/E ratio 2023 |
-13.9
x | Employees | 11 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.9% |
More Fundamentals
* Assessed data
More news
| 1 day | +45.38% | ||
| 1 week | +61.14% | ||
| Current month | +41.16% | ||
| 1 month | +33.08% | ||
| 3 months | +4.09% | ||
| 6 months | -4.29% | ||
| Current year | +5.31% |
1 week
16.40
30.00
1 month
16.4030.00
Current year
16.4030.00
1 year
16.4032.95
3 years
16.4098.30
5 years
14.5098.30
10 years
14.5098.30
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Shen Hsu
CEO | Chief Executive Officer | - | 15-03-31 |
Pi Jung Chen
CHM | Chairman | - | 14-03-16 |
Jung Tun Su
AUD | Comptroller/Controller/Auditor | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yi Hsu Huang
BRD | Director/Board Member | - | 16-04-05 |
Wei Hsiu Wu
BRD | Director/Board Member | - | 18-08-05 |
Tzong Li Lee
BRD | Director/Board Member | - | 19-05-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 26.75 | +45.38% | 648,529 |
| 24-04-24 | 18.4 | +7.29% | 32,460 |
| 24-04-23 | 17.15 | +2.69% | 11,502 |
| 24-04-22 | 16.7 | -1.76% | 25,101 |
| 24-04-19 | 17 | +2.41% | 28,449 |
End-of-day quote Taipei Exchange, April 24, 2024
More quotes
Advagene Biopharma Co., Ltd. is a Taiwan-based company mainly enagegd in the research and development of new drug products through its detoxified LT adjuvant technology platform. The products developed by the Company include nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy) and other vaccines. The detoxified LT adjuvant is genetically engineered to detoxify the heat-labile LT protein (or Escherichia coli heat-labile enterotoxin protein) produced by Escherichia coli.
| 1st Jan change | Capi. | |
|---|---|---|
| +5.31% | 30.08M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- 6709 Stock
